抗糖尿病新药——二肽基肽酶4抑制剂研究进展

被引：11

作者：

刘景龙

环奕

申竹芳

机构：

[1] 中国医学科学院、北京协和医学院药物研究所天然药物活性物质与功能国家重点实验室

来源：

中国临床药理学杂志 | 2012年 / 28卷 / 01期

关键词：

二肽基肽酶4抑制剂; 2型糖尿病; β细胞; 糖化血红蛋白;

D O I：

10.13699/j.cnki.1001-6821.2012.01.024

中图分类号：

R977.15 [];

学科分类号：

摘要：

二肽基肽酶4(DPP4)抑制剂是近年上市的治疗2型糖尿病的新型药物,DPP4抑制剂具有增加GLP-1活性、改善糖脂代谢、减少β细胞凋亡和促进β细胞增殖作用。在2型糖尿病患者中,具有降低HbA1c水平、减少低血糖和副反应发生的作用。DPP4抑制剂作用于新靶点,具有其独特的优点,将会是一类优良的抗糖尿病新药。

引用

页码：67 / 71

页数：5

共 15 条

[1]

Sitagliptin (MK0431) Inhibition of Dipeptidyl Peptidase IV Decreases Nonobese Diabetic Mouse CD4^sup +^ T-Cell Migration Through Incretin-Dependent and -Independent Pathways.[J].Kim; Su-Jin;Nian; Cuilan;McIntosh; Christopher H S.Diabetes.2010, 7

[2]

Effects of Sitagliptin Treatment on Dysmetabolism; Inflammation; and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat).[J].Liliana Ferreira;Edite Teixeira-de-Lemos;Filipa Pinto;Belmiro Parada;Cristina Mega;Helena Vala;Rui Pinto;Patrícia Garrido;José Sereno;Rosa Fernandes;Paulo Santos;Isabel Velada;Andreia Melo;Sara Nunes;Frederico Teixeira;Flávio Reis;Gema Frühbeck.Mediators of Inflammation.2010,

[3]

Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.[J].Xibao Liu;Norio Harada;Shunsuke Yamane;Lisa Kitajima;Saeko Uchida;Akihiro Hamasaki;Eri Mukai;Kentaro Toyoda;Chizumi Yamada;Yuichiro Yamada;Yutaka Seino;Nobuya Inagaki.Life Sciences.2009, 25

[4]

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.[J].James Mu;Aleksandr Petrov;George J. Eiermann;John Woods;Yun-Ping Zhou;Zhihua Li;Emanuel Zycband;Yue Feng;Lan Zhu;Ranabir Sinha Roy;Andrew D. Howard;Cai Li;Nancy A. Thornberry;Bei B. Zhang.European Journal of Pharmacology.2009, 1

[5]

Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings? [J].

Giugliano, Dario ;

Standl, Eberhard ;

Vilsboll, Tina ;

Betteridge, John ;

Bonadonna, Riccardo ;

Campbell, Ian W. ;

Schernthaner, Gerit-Holger ;

Staels, Bart ;

Trichopoulou, Antonia ;

Farinaro, Eduardo .

ACTA DIABETOLOGICA, 2009, 46 (03) :173-181

[6]

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus [J].

Tahrani, Abd A. ;

Piya, Milan K. ;

Barnett, Anthony H. .

ADVANCES IN THERAPY, 2009, 26 (03) :249-262

[7]

DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy [J].

Argyrakopoulou, Georgia ;

Doupis, John .

ADVANCES IN THERAPY, 2009, 26 (03) :272-280

[8]

Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation [J].

Kim, Su-Jin ;

Nian, Cuilan ;

Doudet, Doris J. ;

McIntosh, Christopher H. S. .

DIABETES, 2009, 58 (03) :641-651

[9]

Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA1c level, glucose intolerance, and lipid parameter level in streptozotocin–nicotinamide-induced diabetic mice [J].

Akiko Matsuyama-Yokono ;

Atsuo Tahara ;

Ryosuke Nakano ;

Yuka Someya ;

Masahiko Hayakawa ;

Masayuki Shibasaki .

Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379

[10]

Pharmacokinetic; pharmacodynamic; and efficacy profiles of alogliptin; a novel inhibitor of dipeptidyl peptidase-4; in rats; dogs; and monkeys.[J].Bumsup Lee;Lihong Shi;Daniel B. Kassel;Tomoko Asakawa;Koji Takeuchi;Ronald J. Christopher.European Journal of Pharmacology.2008, 1

← 1 2 →